{"id":"pemivibart","_chembl":{"chemblId":"CHEMBL6068488","moleculeType":"Antibody"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PEMIVIBART","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:07:04.932632+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:07:10.575218+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PEMIVIBART","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:07:11.008279+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068488/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:07:11.701625+00:00"}},"_dailymed":{"setId":"0bdc20a9-791f-9a06-e063-6394a90a84cc","title":"PEMGARDA (PEMIVIBART) INJECTION [INVIVYD, INC]"},"_scrapedAt":"2026-03-28T05:37:02.098Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:07:13.326357+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT06039449","phase":"PHASE3","title":"A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2","status":"COMPLETED","sponsor":"Invivyd, Inc.","startDate":"2023-09-08","conditions":"COVID-19, SARS-CoV-2","enrollment":790}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"INFUSION RELATED REACTION"},{"count":4,"reaction":"PRURITUS"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"VOMITING"},{"count":1,"reaction":"BACK PAIN"},{"count":1,"reaction":"COVID-19"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"DYSPNOEA EXERTIONAL"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"HYPERSENSITIVITY"}],"crossReferences":{"chemblId":"CHEMBL6068488"},"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"PEMIVIBART","genericName":"PEMIVIBART","companyName":"","companyId":"","modality":"Monoclonal antibody","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:07:13.326357+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}